Biomarin Pharmaceutical Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh (B1MR34) Stock Price & Analysis

B1MR34 Stock Chart & Stats

R$157.60R$0.00(0.00%)

At close: Nov 13

Day’s Range: BRL 157.60 - BRL 194.09
52-Week Range: BRL 120.00 - BRL 194.09
Previous Close: BRL 157.60
Volume: N/A
Average Volume (3M): 5
Market Cap: BRL 62.23B
Enterprise Value: BRL 78.20B
Total Cash (Recent Filing): N/A
Total Debt (Recent Filing): N/A
Price to Earnings (P/E): ―
Beta: -0.36
Next Earnings: Feb 24, 2027 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Biomarin Pharmaceutical Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh News

BioMarin price target lowered to $103 from $119 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on BioMarin (BMRN) to $103 from $119 and keeps an Overweight rating on the shares. The firm adjusted estimates and targets among its

1d agoBMRN BM8

BioMarin price target lowered to $86 from $87 at JPMorgan

JPMorgan lowered the firm’s price target on BioMarin (BMRN) to $86 from $87 and keeps an Overweight rating on the shares. Published first on TheFly – the ultimate source for

1w agoBMRN BM8

BioMarin’s Buy Rating Reaffirmed as Diversified Rare-Disease Portfolio Supports Unchanged $97 Price Target

BioMarin Pharmaceutical, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst David Lebowitz from BMO Capital maintained a Buy rating on the stock and has a

1w agoBMRN BM8

BioMarin price target lowered to $60 from $62 at RBC Capital

RBC Capital lowered the firm’s price target on BioMarin (BMRN) to $60 from $62 and keeps a Sector Perform rating on the shares after its in-line Q3 results. The firm

1w agoBMRN BM8

BioMarin price target lowered to $89 from $94 at Wedbush

Wedbush lowered the firm’s price target on BioMarin (BMRN) to $89 from $94 and keeps an Outperform rating on the shares. The firm says the share price drop on the

1w agoBMRN BM8

BioMarin’s Resilient Growth Outlook Supports Buy Rating Despite Price-Target Cut to $89

BioMarin Pharmaceutical, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yun Zhong from Wedbush maintained a Buy rating on the stock and has a $89.00

1w agoBMRN BM8

BioMarin price target lowered to $94 from $97 at Oppenheimer

Oppenheimer analyst Leland Gershell lowered the firm’s price target on BioMarin (BMRN) to $94 from $97 and keeps an Outperform rating on the shares following quarterly results. The firm notes

1w agoBMRN BM8

BioMarin price target lowered to $83 from $86 at BofA

BofA lowered the firm’s price target on BioMarin (BMRN) to $83 from $86 and keeps a Buy rating on the shares. After an “in-line quarter,” the firm notes that the

1w agoBMRN BM8

BioMarin price target lowered to $66 from $70 at Stifel

Stifel lowered the firm’s price target on BioMarin (BMRN) to $66 from $70 and keeps a Hold rating on the shares. Published first on TheFly – the ultimate source for

1w agoBMRN BM8

BioMarin price target lowered to $119 from $122 at Morgan Stanley

Morgan Stanley analyst Sean Laaman lowered the firm’s price target on BioMarin (BMRN) to $119 from $122 and keeps an Overweight rating on the shares. BioMarin delivered its first quarter

1w agoBMRN BM8

BioMarin’s Timing-Related Setback Masks Long-Term Growth Potential, Supporting a Buy Rating with 32.3% Upside

BioMarin Pharmaceutical, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Eric Joseph from Citi reiterated a Buy rating on the stock and has a $76.00

1w agoBMRN BM8

Closing Bell Movers: Apple slips despite earnings beat

Oil and Treasury yields buckled on Monday, and yet the early-session dip-buying in the Tech arena – beaten down last week by post-earnings sell-offs among hyperscalers – fizzled by mid-day.

1w agoBE FN

BioMarin reports Q3 non-GAAP EPS 23c vs. 12c last year

Reports Q3 revenue $1.025B, consensus $1.02B. “BioMarin (BMRN) delivered a strong quarter, with revenue growth of 32%, driven by a more diversified portfolio following the acquisition of Amicus Therapeutics earlier

1w agoBMRN BM8

BioMarin: Buy Rating Reiterated as Rare-Disease Portfolio, LA-GLA Deal & FOLD Acquisition Underscore Upside with Unchanged $114 Price Target

BioMarin Pharmaceutical, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Whitney Ijem from Canaccord Genuity maintained a Buy rating on the stock and has a

2w agoBMRN BM8

B1MR34 FAQ

What was Biomarin Pharmaceutical Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh’s price range in the past 12 months?

Biomarin Pharmaceutical Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh lowest stock price was R$120.00 and its highest was R$194.09 in the past 12 months.

What is Biomarin Pharmaceutical Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh’s market cap?

Biomarin Pharmaceutical Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh’s market cap is R$62.23B.

When is Biomarin Pharmaceutical Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Biomarin Pharmaceutical Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh’s earnings last quarter?

Biomarin Pharmaceutical Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh released its earnings results on Nov 02, 2026. The company reported -R$0.002 earnings per share for the quarter.

Is Biomarin Pharmaceutical Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Biomarin Pharmaceutical Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh pay dividends?

Biomarin Pharmaceutical Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh does not currently pay dividends.

What is Biomarin Pharmaceutical Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh’s EPS estimate?

Biomarin Pharmaceutical Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Biomarin Pharmaceutical Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh have?

Biomarin Pharmaceutical Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh has 193,694,730 shares outstanding.

What happened to Biomarin Pharmaceutical Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh’s price movement after its last earnings report?

Biomarin Pharmaceutical Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh reported an EPS of -R$0.002 in its last earnings report. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Biomarin Pharmaceutical Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh?

Currently, no hedge funds are holding shares in BR:B1MR34

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Biomarin Pharmaceutical Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh (B1MR34) Earnings & Revenues

Historic Earnings Reports

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	15	3	4
Technical Analysis	3	3	4
Moving Averages	12	0	0

Technical Analysis >

Similar Stocks

Stocks similar to BR:B1MR34
Company	Price & Change	Follow
BR:A2RR34Arrowhead Pharmaceuticals Inc Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh
BR:E2XE34Exelixis Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh
BR:R1DY34Dr Reddy'S Laboratories Ltd ADR Unsponsored Brazilian Depositary Receipt Repr 0.16666667 ADR
BR:R2GE34Repligen Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.033333 Sh
BR:T1CH34Bio-Techne Corporation Unsponsored Brazilian Depository Receipt Repr 0.033333333 Sh

Compare BR:B1MR34 Stocks >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft

B1MR34 Stock Chart & Stats

Biomarin Pharmaceutical Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh News

BioMarin price target lowered to $103 from $119 at Morgan Stanley

BioMarin price target lowered to $86 from $87 at JPMorgan

BioMarin’s Buy Rating Reaffirmed as Diversified Rare-Disease Portfolio Supports Unchanged $97 Price Target

BioMarin price target lowered to $60 from $62 at RBC Capital

BioMarin price target lowered to $89 from $94 at Wedbush

BioMarin’s Resilient Growth Outlook Supports Buy Rating Despite Price-Target Cut to $89

BioMarin price target lowered to $94 from $97 at Oppenheimer

BioMarin price target lowered to $83 from $86 at BofA

BioMarin price target lowered to $66 from $70 at Stifel

BioMarin price target lowered to $119 from $122 at Morgan Stanley

BioMarin’s Timing-Related Setback Masks Long-Term Growth Potential, Supporting a Buy Rating with 32.3% Upside

Closing Bell Movers: Apple slips despite earnings beat

BioMarin reports Q3 non-GAAP EPS 23c vs. 12c last year

BioMarin: Buy Rating Reiterated as Rare-Disease Portfolio, LA-GLA Deal & FOLD Acquisition Underscore Upside with Unchanged $114 Price Target

B1MR34 FAQ

Biomarin Pharmaceutical Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh (B1MR34) Earnings & Revenues

Technical Analysis

Overall Consensus

Similar Stocks

Popular Stocks

Become an Expert with TipRanks Premium